Decoding health through molecular insight.

Aitiologic is a precision medicine startup providing multi-modal liquid biopsy solutions for early disease detection and targeted therapy.

Platform

Technology foundation and first applications.

We are building the first multi-modal liquid biopsy platform to decode genomic, epigenomic, and fragmentomic cfDNA signals at single-molecule resolution from a simple blood draw.

Technology

aitios® Platform

Foundational multi-modal liquid biopsy platform for tissue-resolved cfDNA signal interpretation.

Explore

Application

aitios® NIPPT

First-trimester Non-Invasive Prenatal and Preeclampsia Testing for early risk stratification.

Explore

Updates

Latest news and events.

AJOG Global Reports

June 2026

First-Trimester Multi-modal cfDNA Analysis for Prediction of Preterm and Term Preeclampsia

First-trimester multi-modal, tissue-resolved cfDNA analysis enables early risk stratification across the full clinical spectrum of preeclampsia from a single routine blood sample.

Read in AJOG Global Reports

White Paper

May 2026

Screening is the adherence prevention

Aspirin works. Yet U.S. preeclampsia rates keep rising. The failure is not pharmacological — it is a failure of risk identification that asks 9 in 10 pregnant women to take a drug they will rationally decline. A look at the evidence for why first-trimester multi-modal screening, not broader checklists, will finally close the preeclampsia prevention gap.

Read white paper

Upcoming event

LISAvienna Regulatory Affairs Conference 2026

Oct 15, 2026 | Vienna, Austria

Meet us at LISAvienna Regulatory Affairs Conference 2026 in Vienna to discuss regulatory pathways for in-vitro diagnostics and precision diagnostics.

Meet us

Dec 6, 2025

Aitiologic Takes on Preeclampsia: Preparing for Large-Scale Validation after Presentation of Feasibility Study at FMF Conference in London

Aitiologic's Chief Medical Officer, Dr. Rebecca Ertl, presented the first feasibility results of the aitios® platform for tissue-specific liquid biopsy to over 1,500 clinicians and researchers.

Open article

Oct 4, 2024

Aitiologic developing liquid biopsy platform assay for tissue-of-origin analysis, early disease detection

Precision medicine startup Aitiologic is developing a liquid biopsy assay and analysis platform that hopes to enable early disease detection by harnessing both the genetic and epigenetic signatures of cell-free DNA from blood samples.

Read on GenomeWeb

Network & Development Partners